This project, now in production, was subsequently followed by a further expansion. We are currently designing and have just started the construction phase of a €200m new cell culture and purification facility at the site.
Genzyme Flanders bvba, a subsidiary of the US biotechnology company Genzyme, has a facility in Geel which produces a treatment for B-cell lymphocytic leukemia and a rare and often fatal muscle disorder, Pompe disease.
We developed a concept for conversion of the single-product facility, with minimal production interruption, into a facility that will produce two products concurrently. The scope included adding additional bioreactor capacity (two 4,000L Perfusion bioreactors), a new cold purification train, additional buffer preparation facilities and CIP skids. It also involved modification of the existing cell culture (two 10,000L fed batch bio-reactors) and purification train to facilitate production of an alternative product. The majority of the changes were required in the purification suites and required reconfiguration of the existing train to fit the required process flow and add additional unit operations.
PM Group services provided include:
- Project Management
- Conceptual Design
- Preliminary Engineering
- Permitting
- Detailed Design
- Procurement
- Construction Management
- Commissioning
The PM Group team has since completed the design and construction management of a further significant production expansion at the facility. Since early 2010, we have been designing the latest and largest expansion worth €200m on the site. This project started construction in late 2010 and PM Group is providing full service architecture, engineering, procurement, project and construction management services.